Daily Medication Pearl: Solriamfetol (Sunosi) for Excessive Daytime Sleepiness

The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Medication Pearl of the Day: Solriamfetol (Sunosi)

Indication: Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Insight:

  • Dosing: Starting dose for patients with narcolepsy is 75 mg once daily. Starting dose for patients with OSA is 37.5 mg once daily. Dose may be increased at intervals of at least 3 days. Maximum dose is 150 mg once daily.
  • Dosage form: Tablets 75 mg (functionally scored) and 150 mg.
  • Adverse events (AEs): Most common AEs are headache, nausea, decreased appetite, insomnia, and anxiety.
  • Mechanism of action: The mechanism of action of solriamfetol is thought to be mediated through its activity as a dopamine and DNRI.
  • Manufacturer: Jazz Pharmaceuticals

Sources: